It is intended to provide a gene regulating the production of amyloid β protein, a protein and use thereof.

It is intended to provide a gene controlling the production of amyloid β protein.

Existing medications have mostly sought to inhibit the protein amyloid beta.

The absence of the p62 protein has a profound effect on the accumulation of tau protein, amyloid beta protein and an increase in blood insulin levels.

J147 has also been used to target the buildup of the protein beta-amyloid.

One of the proteins studied, the protein beta-amyloid, accumulates in Alzheimer's disease.

One of the proteins studied, the protein beta-amyloid, accumulates in Alzheimer's disease.

Beta-amyloid protein is a primary risk factor for Alzheimer’s.

Neurones were also more likely to be primed to express amyloid-beta protein and tau.

Bexarotene reduced the ability of beta-amyloid protein pieces to stick together.

These antibodies have also been able to stop the effect of accumulation of the protein beta-amyloid.

The average PET scan score indicating the amount of amyloid beta protein in the brain after being compared with a part of the brain where amyloid beta doesn’t accumulate was 1.2.

The accumulation of tau protein and amyloid beta protein in neurological tissues is a hallmark of neurological metabolic diseases such as Alzheimer's Disease and related dementias.

These antibodies have also been able to stop the effect of accumulation of the protein beta-amyloid.

The average PET scan score indicating the amount of amyloid beta protein in the brain after being compared with a part of the brain where amyloid beta doesn't accumulate was 1.2.